Kyungdong Pharmaceutical Signs Licensing Agreement for Prostate Cancer Treatment with Owl Bio

Kyungdong Pharmaceutical announced on the 26th that it has signed a licensing agreement for AUL010, a treatment for prostate cancer and precocious puberty, with Owl Bio.

AUL010 is a one-month sustained-release leuprorelin formulation for the treatment of prostate cancer and precocious puberty. Kyungdong Pharmaceutical will be responsible for clinical trials (bioequivalence tests), regulatory approval, and product sales, while Owl Bio will handle the production and supply of the product.

Leuprorelin is a drug used to treat prostate cancer and precocious puberty. The domestic market is estimated to be about 80 billion KRW. In Korea, approved leuprorelin formulations include the original drug "Lupron Injection" by Takeda Korea and several generic products, but there are not many due to the technological barriers of long-acting injectable formulations. Therefore, through this agreement, both companies expect to provide stable and effective treatment to more patients.

Kim Kyunghoon, CEO of Kyungdong Pharmaceutical, stated, “With the introduction of a long-acting injectable formulation applying Owl Bio’s innovative drug delivery technology, we will be able to offer another option to patients with precocious puberty and prostate cancer.” He added, “We will continue to strive to improve patient medication adherence and quality of life through various long-acting injectable drugs developed in cooperation between the two companies.”

Meanwhile, Kyungdong Pharmaceutical signed a memorandum of understanding (MOU) with Owl Bio last year and is pursuing a strategy to secure continuous future growth engines by jointly developing some of its new drug pipelines through strategic investment.

This content was produced with the assistance of AI translation services.